Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Thursday, ...
20 Février 2014 - 2:00PM
Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it
will host a webcast and conference call to discuss the Company's
financial results for the quarter and year ended December 31, 2013,
and provide a general business overview on Thursday, February 27,
2014, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Conference Call Details
To access the live conference call, please dial (866) 318-8611
from the U.S. and Canada or +1(617) 399-5130 internationally, and
use the passcode 38755086. Please dial in 10 minutes prior to the
start of the call.
To access the live and subsequently archived webcast of the
conference call, go to the Investor Relations section of the
company's website at http://investors.portola.com. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary. A replay of the
webcast will be available on the Company's website for 30 days
following the live event.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company focused
on the development and commercialization of novel therapeutics in
the areas of thrombosis and hematology.
Betrixaban
Portola's wholly-owned lead compound, betrixaban, is a novel,
oral, once-daily Factor Xa inhibitor in Phase 3 development for
extended-duration prophylaxis of venous thromboembolism (VTE) in
acute medically ill patients. Betrixaban's properties may be
uniquely suited to potentially demonstrate efficacy without
significantly increasing bleeding in this patient population.
Currently, there is no anticoagulant approved for extended-duration
VTE prophylaxis in acute medically ill patients.
Andexanet Alfa*
Portola's second lead development candidate, andexanet alfa
(PRT4445), has the potential to be a first-in-class reversal agent
to directly reverse the effects of Factor Xa inhibitors in patients
who suffer a major bleeding episode or who require emergency
surgery. Portola has entered into clinical collaboration agreements
with all of the manufacturers of direct Factor Xa inhibitors,
including Bristol-Myers Squibb and Pfizer (Eliquis® [apixaban]),
Bayer HealthCare and Janssen Pharmaceuticals (XARELTO®
[rivaroxaban]), and Daiichi Sankyo (Savaysa™ [edoxaban]), while
retaining all commercial rights to the program. Andexanet alfa has
been designated as a breakthrough therapy by the U.S. Food and Drug
Administration.
Cerdulatinib* (PRT2070) and PRT2607
Portola's third wholly-owned product candidate, cerdulatinib
(PRT2070), is an orally available kinase inhibitor that uniquely
inhibits two validated tumor proliferation pathways -- spleen
tyrosine kinase (Syk) and janus kinase (JAK). It is currently being
studied in patients with leukemias or lymphomas with a focus on
genetically-defined subtypes, as well as in patients who have
failed therapy due to relapse or acquired mutations. Portola's
fourth program is partnered with Biogen Idec and is focused on the
development of PRT2607, a selective Syk inhibitor.
For more information, visit www.portola.com and follow the
company on Twitter @Portola_Pharma.
*Andexanet alfa and cerdulatinib are proposed International
Nonproprietary Names (pINN).
CONTACT: Investor Contact:
Alexandra Santos
Portola Pharmaceuticals
ir@portola.com
650.246.7239
Media Contact:
Joey Fleury
BrewLife
jfleury@brewlife.com
415.946.1090
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024